{"url_path":"/sec/lnai/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1527728/0001731122-26-000749-index.html","accession_number":"0001731122-26-000749","cik":"0001527728","ticker":"LNAI","issuer_name":"Lunai Bioworks Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1527728/0001731122-26-000749-index.html","primary_entity_key":"0001527728","primary_entity_name":"Lunai Bioworks Inc."},"word_count":662,"has_tables":true,"body_markdown":"**Item 6. Exhibits.**\n\n \n\nExhibits required by Item 601 of Regulation S-K:\n\n \n\nExhibit No.\n \nDescription\n\n \n \n \n\n 2.1\n \n[Agreement and Plan of Merger, dated February 26, 2025, by and among Renovaro, Inc, Renovaro Acquisition Sub and Biosymetrics, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the SEC on February 28, 2025)](http://www.sec.gov/Archives/edgar/data/1527728/000173112225000312/e6390_ex2-1.htm)\n\n2.2\n \n[Agreement and Plan of Merger, dated as of April 27, 2026, by and among Lunai Bioworks, Inc., Lunai Bioworks IP, Inc., Neurobridge IP Holdings Incorporated, Oncotelic Inc., and Pelerin Therapeutics Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed with the SEC on April 29, 2026).ertificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q filed with the SEC on February 14, 2024)](http://www.sec.gov/Archives/edgar/data/1527728/000173112224000248/e5415_ex3-1.htm)\n\n3.1\n \n[Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Form 10-Q filed with the SEC on February 14, 2024)](http://www.sec.gov/Archives/edgar/data/1527728/000173112224000248/e5415_ex3-1.htm)\n\n3.2\n \n[Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.1 to Form 8-K filed with the SEC on May 24, 2024)](http://www.sec.gov/Archives/edgar/data/1527728/000173112224000883/e5703_ex3-1.htm)\n\n 3.3\n \n[Certificate of Designation of Series B Convertible Preferred Stock of Lunai Bioworks, Inc., as filed with the Secretary of State of the State of Delaware on May 1, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the SEC on May 5, 2026). ](http://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/e7595_ex3-1.htm)\n\n10.1†\n \n[Employment Agreement by and between Nathen Fuentes and Renovaro Inc., dated as of January 6, 2025. (incorporated by reference to Exhibit 10.2 to the Company’s Form 10-Q filed with the SEC on February 19, 2025)](http://www.sec.gov/Archives/edgar/data/1527728/000173112225000258/e6372_ex10-2.htm)\n\n10.2\n \n[Form of Exchange Agreement (incorporated herein by reference to Exhibit 99.1 to Form 8-K filed with the SEC on July 9, 2025)](http://www.sec.gov/Archives/edgar/data/1527728/000173112225000948/e6687_ex99-1.htm)\n\n10.3\n \n[Form of Debt Exchange Agreement, dated as of March 24, 2026, between Lunai Bioworks, Inc. and certain Holders (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on March 30, 2026).](http://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/e7507_ex10-1.htm)\n\n10.4\n \n[Form of Common Stock Purchase Warrant, dated as of March 24, 2026, issued by Lunai Bioworks, Inc. (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on March 30, 2026). ](http://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/e7507_ex4-1.htm)\n\n10.5\n \n[Securities Purchase Agreement, dated as of November 24, 2025, between Lunai Bioworks, Inc. and the Investor named therein (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on November 24, 2025).](http://www.sec.gov/Archives/edgar/data/1527728/000173112225001597/e7070_ex1-1.htm)\n\n10.6 \n \n[At-the-Market Sales Agreement, dated as of December 2, 2025, between Lunai Bioworks, Inc. and Dawson James Securities, Inc. (incorporated by reference to Exhibit 1.1 to the Company’s Form 8-K filed with the SEC on December 3, 2025).](http://www.sec.gov/Archives/edgar/data/1527728/000173112225001625/e7056_ex1-1.htm)\n\n31.1**\n \n[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 ](e7638_ex31-1.htm)\n\n31.2** \n \n[Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 ](e7638_ex31-2.htm)\n\n32.1***\n \n[Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350](e7638_ex32-1.htm)\n\n32.2***\n \n[Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350](e7638_ex32-2.htm)\n\n \n \n \n\n101.INS\n \nXBRL Instance Document\n\n \n \n \n\n101.SCH\n \nXBRL Taxonomy Extension Schema\n\n \n \n \n\n101.CAL\n \nXBRL Taxonomy Extension Calculation Linkbase\n\n \n \n \n\n101.DEF\n \nXBRL Taxonomy Extension Definition Linkbase\n\n \n \n \n\n101.LAB\n \nXBRL Taxonomy Extension Label Linkbase\n\n \n \n \n\n101.PRE\n \nXBRL Taxonomy Extension Presentation Linkbase\n\n104\n \nCover Page Interactive Data File (formatted as Inline XBRL and contained\nin Exhibit 101)\n\n \n\n**\nFiled herewith. \n\n***\nFurnished herewith.\n\n†\nDenotes a management contract or compensatory plan or arrangement\n\n \n\n40\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of\nSection 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the\nundersigned, thereunto duly authorized.\n\n \n\nDate: May 15, 2026\n**LUNAI BIOWORKS INC.**\n\n \n \n \n\n \nBy:\n*/s/ David Weinstein*\n\n \n \nDavid Weinstein\n\n \n \nChief Executive Officer\n\n \n \n(Principal Executive Officer)\n\n \n \n \n\n \nBy:\n*/s/ Nathen Fuentes*\n\n \n \nNathen Fuentes\n\n \n \nChief Financial Officer\n\n \n \n(Principal Financial and Accounting Officer)\n\n \n\n41"}